OVA-E1 peptide

• Description:

  OVA-E1 peptide, is an antagonist variant of SIINFEKL [OVA (257-264) . OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes[1].

• UNSPSC:

  12352209

• Hazard Statement:

  H315-H319-H335

• Target:

  JNK; p38 MAPK

• Type:

  Peptides

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ova-e1-peptide.html

• Solubility:

  H2O

• Smiles:

  O=C (N[C@@H] ([C@@H] (C) CC) C (N[C@@H] ([C@@H] (C) CC) C (N[C@@H] (CC (N) =O) C (N[C@@H] (CC1=CC=CC=C1) C (N[C@@H] (CCC (O) =O) C (N[C@@H] (CCCCN) C (N[C@@H] (CC (C) C) C (O) =O) =O) =O) =O) =O) =O) =O) [C@H] (CCC (O) =O) N

• Molecular Formula:

  C47H76N10O14

• Molecular Weight:

  1005.16

• Precautions:

  P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Leandro J Carreño, et al. The Half-Life of the T-cell receptor/peptide-major Histocompatibility Complex Interaction Can Modulate T-cell Activation in Response to Bacterial Challenge. Immunology. 2007 Jun;121 (2) :227-37.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported

• CAS Number:

  153316-01-9